This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Primary objective: To determine the effectiveness of organisation-wide interventions to implement person-centred care for people with dementia, in relation to reduction of behavioural symptoms such as agitation and depression, improvement in quality of life and functional capabilities, alterations in the use of restraint (physical and/or chemical) and reduction in adverse events. Secondary objective: To identify the variety, quality, and feasibility of person-centred care approaches for people with dementia, with specific reference to organisational factors which promote and constrain the implementation of person-centred care.
T A B L E O F C O N T E N T S B A C K G R O U N D

Description of the condition
In developed countries, dementia is one of the leading causes of disability in people aged over 65 years. It occurs in people of all cultures and is becoming increasingly common in countries whose populations are ageing. Worldwide there are over 7.7 million new cases of dementia each year. Approximately 60% of this disease burden and the most rapid growth in prevalence in the next decade (77% to 146%) will fall on low-and middle-income countries which have the least capacity to cope (World Health Organisation 2015) . As population ageing continues to accelerate, the number of people with dementia is expected to nearly double every 20 years, growing to 65.7 million worldwide by 2030 (Alzheimer's Association 2013) . Despite wide variations in the proportions of formal and informal care arrangements for people with dementia in different regions of the world, there are similar social and economic costs (World Health Organisation 2014) . Dementia is classified in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association 2013) as a major neurocognitive disorder, encompassing a range of degenerative conditions characterised by progressive decline in cognition and impairment in function. It is typically irreversible; currently there is no approved treatment available to prevent progression or to cure the disease. The most common type of dementia is Alzheimer's disease (approximately 50% to 75%), which occurs usually after 65 years of age and is characterised by the accumulation of abnormal proteins in the brain in the form of amyloid plaques and neuritic tangles (Alzheimer's Disease International 2013). The next most common type is vascular dementia (20% to 40%), which results from decreased blood flow and hence impaired supply of oxygen and nutrients to the brain. Brain damage from major vascular events usually progresses in a step-wise fashion of deterioration and stabilisation, but disease of the small intracerebral vessels typically presents as dementia with a more insidious course. Death often occurs following a major stroke (Alzheimer's Association 2014a). Dementia with Lewy bodies (DLB) and dementia in Parkinson's disease (PDD) are closely related conditions in which degeneration of nerve cells is again thought to be due to abnormal protein deposits, in this case in the form of intracellular Lewy bodies (Alzheimer's Australia 2013). Frontotemporal dementia (FTD) often commences between 40 and 65 years of age, occurs in 5% to 10% of cases of dementia, and is associated with a variety of pathologies (Alzheimer's Australia 2013). With older age, the cause of dementia is more likely to be mixed, with combinations of Alzheimer's and vascular pathology being most common, although other mixed pathologies also occur. Early-onset dementia describes any form of dementia occurring in people under 65 years of age, with the main subtypes being alcohol-related dementia (22%), Alzheimer's disease (16%), frontotemporal dementia (13%) and vascular dementia (10%) (Draper 2011) . Other forms of dementia occur with Korsakoff Syndrome, Huntington's disease, traumatic brain injury and HIV/AIDS (Alzheimer's Association 2014b). There are often subtle changes in a person's behaviour and function before the formal diagnostic criteria for dementia are met. Symptoms typically include impairment of language, memory, perception, personality and cognitive skills. As the disease progresses there will be a decline in intellect, judgement, social skills, ability to manage daily functions and socially-tolerated emotional reactions. Some of the psychological responses in people with dementia include depression, psychosis, aggression and wandering from home (Alzheimer's Association 2013). Criteria for diagnosing dementia are outlined in the DSM-5 (American Psychiatric Association 2013). Cognitive changes must be assessed relative to the person's background cognitive ability, using culturally-sensitive and validated measures of physical and psychosocial function. This is especially important for people outside societal 'norms', including high-functioning individuals (who may not fit usual diagnostic criteria for dementia), those with special needs such as people with cultures and languages different from the mainstream society, and those with younger onset dementia and intellectual disability. Cognitive assessments need to be supplemented by a detailed longitudinal account, provided by an informant, of the person's health and social history with a focus on functional impairment. When appropriate measurement and interviewing styles are utilised in a quiet, safe and relaxed environment, people with dementia can provide reliable self-reports about their daily living activities and past life experiences. Utilising reminiscence during the interview assists in attending to cues and explicit references to symptoms conveyed by the person (Clare 2005; Clark 2008; Kolanowski 2007) . A physical examination and clinical investigations should also be conducted to rule out reversible causes.
Description of the intervention
Person-centred approaches to dementia care are based on the notion that the unique identity, personality and subjective reality of person living with dementia remain, despite the presence of a disease process (Kitwood 2007) . Carl Rogers, one of the 20th century's most influential humanistic psychologists, founded the person-centred approach to care. "Rogers proposed that a person-centred approach, based on acceptance, caring, empathy, sensitivity, and active listening, promotes optimal human growth" (Brownie 2013, p.2) . As a response to the increasing disenfranchisement of people living with dementia in long-term care homes, social psychologist Tom Kitwood (Kitwood 2007 ) developed a model of person-centred care. His model challenged the notion that dementia leads to a loss of the person and, thus, to faulty interpretations of symptoms associated with dementia. Person-centred care operates from a perspective that many of these symptoms, such as agitation and aggression, are a result of the person's interactions within the psychosocial world. The 'social-psychological theory of personhood in dementia' (Kitwood 2007) is the basis for the person-centred care model, proposing that people exist in a social, relational context, and that positive and enriching interpersonal relationships can prevent the disabling effects of dementia and promote a sense of well-being (Brooker 2003; Davis 2004; Dewing 2008) . The theory recognises the persistence of 'personhood' despite other losses that are occurring in dementia; supported by evidence that people with dementia retain a sense of identity (Rankin 2005) and the ability to communicate their wants, needs and desires (Mayhew 2001) . Person-centred care, therefore, aims to support the person's identity by meeting their needs for love, attachment, comfort, occupation and inclusion. When these psychosocial needs are met, the person will have a sense of self-worth and feel valued, and there will be fewer expressions of ill-being, which are generally expressed in various forms of agitated and/or apathetic behaviour (Brooker 2007a; Slater 2006) . Person-centred care focuses its attention on maintaining and nurturing personhood. Person-centred care achieves its goal by adherence to a set of guiding principles:
1. Create and strengthen a positive relationship with the person through warm and accepting human contact.
2. Communicate respectfully, value and honour the person.
3. Treat the person as a sentient and unique human being, by valuing their innate nature and assisting them to retain their remaining strengths.
4. See the person's world from their perspective in all interactions with them.
5. Help the person to feel socially confident and to maintain emotional attachment to others. 6. Assist the person to have choice and to make decisions about their own life.
7. Make use of the person's positive memories to help improve their self-esteem and maintain their identity. 8. Treat the person's behaviour as a way of communicating their feelings and needs and respond to the behaviour with empathy (Brooker 2007a). Implementing person-centred care means promoting a system of social relationships that have the potential to mitigate the disabling effects of dementia through adherence to these principles in all interactions with the person (Davis 2004) . The model relies on carers 'knowing the person' with dementia, understanding their unique life story, values and belief systems, preferences and idiosyncratic needs. This personal knowledge enables carers to engage with the person with dementia and form meaningful relationships with them. As a result the person with dementia is more secure in their environment, feels acknowledged as a person and is, therefore, less likely to become distressed or agitated. Achieving these desirable outcomes is not only a matter of individuals learning the skills of person-centred care. It requires organisational leadership at all levels in order to address the structural barriers that prevent the adoption and maintenance of system-wide person-centred service, whether the system is a hospital ward, a day centre or a residential care home. The model is best implemented when the entire system is framed by policies to guide implementation across the organisation. All systems must operate to support personhood as the primary aim. This change in ethos requires organisational commitment to person-centred care and the education, training and supervision of all people involved in supporting the person's activities of daily living (Alzheimer's Disease International 2014). A shift in the system's loci of authority, control and power may, therefore, be required to support a person-centred service. A number of different aspects of the organisation have been targeted in implementing person-centred care, including: organisational culture (Caspar 2009; Kane 2007) ; management systems (Miller 2010 
How the intervention might work
As described above, person-centred care challenges the conventional constructions of dementia that can result in depersonalisation, treating the person as if they are no longer 'there' and focusing on their deficits (Davis 2004) . A person-centred approach en-ables carers to interpret the behaviours of a person with dementia, not as a function of their illness, but rather as a response to what is happening to and occurring around them in their psychosocial milieu. Carers come to understand that it is how the person with dementia is being regarded and treated that can trigger behaviours, like aggression and resistance, during care events. The review will consider person-centred interventions within the organisation which aim to support one or more of the 'VIPS' constructs (Røsvik 2013 ):
• Valuing: asserting the absolute value of the person's humanity.
• Individual care: recognising and responding to the person's uniqueness.
• Perspective: interpreting the person's actions/behaviour from their perspective.
• Social psychology: prioritising the person's well-being.
The VIPS constructs are relevant because they operate to support person-centred care across the entire organisation, by enabling the organisational structures that promote implementation.
Why it is important to do this review
Internaionally, people with dementia will eventually need some level of formal health and social care assistance, to complement and/or replace the care and support provided by their families (Alzheimer's Disease International 2014). Formal health and social care services operate in complex systems, which are bounded by the political, policy, economic, social and cultural frameworks unique to each culture and geographical region. While there is no unitary system and level of support that is suitable for all people with dementia, it is incumbent on governments and societies to ensure that, as far as possible, health and social care services are available to people with dementia and their families, and that services are dementia-inclusive (World Health Organisation 2014). Family care for people with dementia is still common practice in most middle-and lower-income countries. In middle-and higherincome countries, the range of services available for the person and their family can include family support and respite, home help, personal care, palliative care, residential and assisted living support, long-term care assistance and nursing care, and hospital care. Each type of service has its own philosophical and policy framework, financial arrangement and requirements in service provision (Alzheimer's Association 2013). Despite these differences, formal service providers have a mandate to provide quality, evidencebased care and support to people with dementia and their families (American Psychiatric Association 2013). When services are dementia-inclusive, that is, they focus effort on adapting services to the needs of the individual, they can improve life for the person and their carer/s (Brownie 2013; León-Salas 2013; NICE 2010) . A small number of dementia care service models have proved effective (Beerens 2013).
One care model which has international appeal and evidence for its effectiveness and efficacy is the person-centred approach advocated by Tom Kitwood (Kitwood 1997) . While there have been some criticisms of the model within the context of care relationships (Adams 2005; Nolan 2006b; Price 2006) , the level of interest in person-centred care is growing. It has been adapted for use in acute, community and long-term care contexts in different cultures and societies (Aged Care Branch 2011; Brownie 2013; Wylie 2002) . Person-centred care has been used as a general approach to improve specific aspects of care and treatment for people with dementia (Brooker 2007a; Fossey 2006; Sloane 2004) , to improve their well-being (Chenoweth 2009; van de Ven 2013) and in helping to reduce various forms of agitation (Cohen-Mansfield 2012). Different approaches/techniques to implementing person-centred care have also proved helpful (Beavis 2002; Brownie 2013) . In many countries, including Australia, the United States, parts of South America and the Caribbean, Canada, the United Kingdom (UK), the Netherlands, Hong Kong, South Korea, Japan and across Scandinavia, quality dementia care is a national health and social priority. The governments of these nations are actively promoting person-centred dementia and aged care (Alzheimer's Association 2013). Given the investments that governments and service providers are making in developing dementia-inclusive services and communities, it is timely to undertake a rigorous review of the different person-centred models and care approaches that are operating across the world. It will be important to advise governments, the health and aged care industries and consumers on the outcomes of these different person-centred models and care approaches for people with dementia, their families and service providers.
O B J E C T I V E S
Primary objective: To determine the effectiveness of organisationwide interventions to implement person-centred care for people with dementia, in relation to reduction of behavioural symptoms such as agitation and depression, improvement in quality of life and functional capabilities, alterations in the use of restraint (physical and/or chemical) and reduction in adverse events.
Secondary objective: To identify the variety, quality, and feasibility of person-centred care approaches for people with dementia, with specific reference to organisational factors which promote and constrain the implementation of person-centred care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all published and unpublished randomised controlled trials (RCTs), including cluster-randomised trials (CRTs), recognising that this limits the review by excluding findings from other designs using qualitative methods. Trials will be included even if the method of sequence generation is sub-optimal ('quasirandomised') or unclear, however the inadequacies of the allocation method will be considered a source of selection bias.
Types of participants
Eligible participants will have been diagnosed with dementia according to the appropriate editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) (American Psychiatric Association 2013) and the International Classification of Diseases (ICD) (World Health Organisation 2015) . If diagnostic information on participants is not described in potentially-relevant studies, study authors will be asked for additional diagnostic information. Participants will be receiving formal dementia care from an organisation which may be an individual care home, a chain of care homes, a hospital or a care agency providing formal care in these organisations.
Types of interventions
We will include interventions which are explicitly intended to promote the implementation of person-centred care at the organisational level, according to the VIPS constructs (Røsvik 2013 ; see How the intervention might work). Interventions may target one or more of: organisational culture; management systems; quality monitoring and improvement systems; staff education and training; and care planning prioritisation. They may also include nursing guidelines or practice guidelines for specific issues such as resistance during personal care, or specific techniques which aim to facilitate person-centred care, including care monitoring and staff support models such as Dementia Care Mapping (Brooker 2011). We will not include interventions with an individual focus, such as personalised activity programmes. The control interventions may either be 'care as usual' or 'standard care'. Studies that compare different approaches to implementing person-centred care will also be considered.
Types of outcome measures
Primary outcomes
• Frequency and severity of behavioural symptoms measured with either multi-faceted scales such as the Neuropsychiatric Inventory (Cummings 1994) , scales specific to agitation such as the Cohen-Mansfield Agitation Inventory (Cohen-Mansfield 1999), or mood scales such as the Cornell Scale of Depression in Dementia (Alexopoulos 1988).
• Quality of life, as measured by validated dementia quality of life instruments.
Secondary outcomes
• Function in activities of daily living.
• Use of physical/mechanical restraint.
• Use of chemical restraint including psychotropics, antihistamines, and sedatives.
• Adverse events such as delirium, falls and related injuries, and pressure ulcers.
Search methods for identification of studies
Relevant studies will be identified by searching various databases.
Electronic searches
We will search ALOIS (www.medicine.ox.ac.uk/alois) -the Cochrane Dementia and Cognitive Improvement Group's (CD-CIG) specialised register. ALOIS is maintained by the Trials Search Co-ordinator for the CDCIG, and contains studies that fall within the areas of dementia prevention, dementia treatment and management, and cognitive enhancement in healthy elderly populations. The studies are identified through:
1. To view a list of all sources searched for ALOIS see About ALOIS on the ALOIS website (www.medicine.ox.ac.uk/alois). Details of the search strategies run in healthcare bibliographic databases, used for the retrieval of reports of dementia, cognitive improvement and cognitive enhancement trials, can be viewed in the 'Methods used in reviews' section within the editorial information about the Cochrane Dementia and Cognitive Improvement Group on The Cochrane Library. We will run additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, ClinicalTrials.gov and the WHO Portal/ ICTRP to ensure that the searches for each suite of reviews is as comprehensive and as up-to-date as possible. The search strategy that will be used for the retrieval of reports of trials from MED-LINE (via the Ovid SP platform) can be seen in Appendix 1.
Searching other resources
We will also:
• handsearch reference lists of all included studies, relevant systematic reviews and other relevant publications;
• contact authors of relevant studies or reviews to clarify reported published information and seek unpublished data;
• conduct cited reference searches for all included studies, in ISI Web of Knowledge.
Data collection and analysis
The first review author (LC) will execute the search strategy as described, supported by the second and third authors (JS-P, SL). Any studies on PCC undertaken by the review authors that are deemed eligible for inclusion in the review will be assessed for study selection, extract data and 'Risk of bias' by an independent reviewer Professor Elizabeth Beattie (EB).
Selection of studies
The search results will be merged using reference management software and duplicate records removed. Two review authors (LC and JS-P) will independently screen the search results at three levels: (1) titles, (2) abstracts to assess which studies satisfy the inclusion criteria, and (3) full text copies of the papers that are potentially relevant. Obviously irrelevant reports will be removed. Multiple reports of the same study will be linked. If the paper cannot be assessed for relevance based on title or abstract, the full text will be obtained. When suitability of a study is unclear, after examining the full text the corresponding author will be contacted to request clarification or additional information, or both.
Data extraction and management
Two review authors (LC and JS-P) will extract data independently using the Template for Intervention Description and Replication (TIDieR) checklist (Hoffmann 2014) . Any discrepancies will be resolved by discussion. The third and fourth review authors (SL and WYA) will be consulted in the case of persistent disagreement.
Assessment of risk of bias in included studies
Two review authors (LC and JS-P) working independently will assess the methodological quality of the included studies using the Cochrane 'Risk of bias' assessment tool . We will assess studies for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and anything else that might lead to a systematic underestimate, or overestimate, of the difference between groups. Two review authors (SL and WYA) will assess the risk of bias independently and discrepancies will be resolved by discussion. An arbitrator will be consulted in the case of persistent disagreement.
Measures of treatment effect
All results will be presented with 95% confidence intervals. Dichotomous data: The effect measure for dichotomous outcomes will be the odds ratio. Continuous data: The effect measure for continuous data will be the mean difference where arithmetic means and standard deviations are provided. If the same outcome is measured using different scales, then the standardised mean difference will be used. Geometric mean ratios will be used if continuous outcomes are summarised using geometric means. Medians and ranges will be reported in a table. Count data: Effect measures for counts and rates will be rate ratios. Time-to-event data: Time-to-event data will be compared using hazard ratios.
Unit of analysis issues
We anticipate including cluster randomised trials. Where these report analyses which account for cluster randomisation, we will check that the method used was appropriate. If no correct analysis accounting for the cluster randomisation is reported, then we will attempt to re-analyse the data following the Cochrane Handbook guidelines . Where studies report outcomes at multiple time points, we will consider meta-analysis using methods described by Peters and Mengersen (Peters 2008) , depending on the availability of summary effects, number of repeated outcome measures, between-subjects and within-subjects variance, difference between outcome measures at different time-points and slope estimate for trend. Meta-analyses will be conducted in the following circumstances:
• given time point, where most studies report one given time point and others report multiple time points;
• first/last time point, where most studies report two time points and a small number of studies report three or more time points; and
• all time points, where most studies report three or more time points.
If a study does not report appropriate results, we will not re-analyse the data because no estimate of within-subjects variation can be obtained and any re-analysis would underestimate, or overestimate, the standard error of the effect sizes. Therefore, as suggested in the Cochrane Handbook guidelines, we will present the results reported in the original papers only.
Dealing with missing data
Authors will be contacted and asked to supply the study protocol and full information for any outcomes reported inadequately. In addition, for outcomes mentioned in articles or protocols but not reported, we will ask authors to clarify whether those outcome measures were in fact analysed, and if so to supply the data. The completeness of outcome data for each main outcome will be described including attrition and exclusions from the analysis. We will report parameters such as the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions and any re-inclusions.
Assessment of heterogeneity
We will report variability between the included studies in terms of study design, participants, settings, interventions, comparisons, outcome assessment and outcome measures. Substantial statistical heterogeneity will be suggested by the following indicators: poor overlap of confidence intervals on forest plots; high Chi 2 values, P > 0.10, and I 2 statistic > 50.
Assessment of reporting biases
The possibility of selective outcome reporting will be examined and reported.
Data synthesis
We will appraise the variability across studies (in terms of participants, interventions, comparisons and outcomes) in order to make rational decisions about pooling data, or making particular comparisons across included studies. This assessment will include clinical heterogeneity and methodological heterogeneity. If studies are found to be sufficiently similar to ensure a clinically meaningful answer, we will use RevMan software to pool the results. If substantial heterogeneity is found, we will report results in a narrative form. Where applicable, we will calculate the relative risk and mean differences with 95% confidence intervals for categorical and continuous data, respectively. We will use a randomeffects model to take into account the (expected) heterogeneity of the various studies. We will examine data from cluster trials with unit of analysis errors according to the Effective Practice and Organisation of Care (EPOC 2015) guidelines, and absolute risk differences will be used.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis, where possible, will be conducted on participant populations, in order to make comparisons between subgroups based on factors such as participant features, or subsets of studies (e.g. study setting and its geographical location).
Sensitivity analysis
If sufficient trials that satisfy the inclusion criteria are identified, we will conduct sensitivity analyses regarding risk of bias to investigate the robustness of the results in relation to the quality components. The effect of missing data will also be investigated using sensitivity analyses.
